GILD - Gilead Sciences - Stock Price & Dividends

Gilead Sciences Inc., a leading biopharmaceutical company, is dedicated to discovering, developing, and commercializing innovative medicines that address significant unmet medical needs globally. With a strong presence in the United States, Europe, and internationally, the company has established itself as a pioneer in the healthcare industry.

The company's portfolio of products is diverse and extensive, with a focus on treating life-threatening diseases such as HIV/AIDS, COVID-19, and viral hepatitis. Its HIV/AIDS treatment options include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla, offering patients a range of choices to manage their condition. For COVID-19, Gilead offers Veklury, an injection for intravenous use, which has been instrumental in combating the pandemic. Additionally, the company's viral hepatitis treatment options include Epclusa, Harvoni, Vemlidy, and Viread, providing patients with effective solutions to manage their condition.

In the field of oncology, Gilead offers Yescarta, Tecartus, and Trodelvy, which have revolutionized the treatment of various types of cancer. The company also provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension, and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead has established strategic collaborations with numerous companies, including Arcus Biosciences, Inc., Merck Sharp & Dohme Corp., Pionyr Immunotherapeutics Inc., and others, to accelerate the development of innovative therapies. These collaborations enable the company to leverage the expertise of its partners and expand its research capabilities, ultimately driving progress in the discovery of new medicines.

In addition to its collaborations, Gilead has a research collaboration, option, and license agreement with Merus N.V. to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies, further solidifying its commitment to advancing cancer research.

Founded in 1987, Gilead Sciences Inc. is headquartered in Foster City, California, and has established itself as a leader in the biopharmaceutical industry. With a strong focus on innovation and patient care, the company continues to drive progress in the discovery and development of life-changing medicines.